Elite *Journal of Scientific Research and Review*. Volume 2 issue 1(2024), Pp. 37-50
https://epjournals.com/journals/EJSRR

Counting Cells, Shaping Fates: CD4/CD8 Ratios in HIV

[*]Emmanuel Ifeanyi Obeagu[1] and Getrude Uzoma Obeagu[2]

[1]Department of Medical Laboratory Science, Kampala International University, Uganda.

[2]School of Nursing Science, Kampala International University, Uganda.

[*]Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161

Abstract

The dynamic interplay between CD4 and CD8 T-cell populations stands as a pivotal aspect of immune function, particularly in the context of HIV infection. The balance between CD4 and CD8 T-cell subsets is fundamental for orchestrating an effective immune response. In the realm of HIV, where the virus specifically targets CD4 T cells, understanding the nuances of CD4/CD8 ratios becomes paramount. The CD4/CD8 ratios have long served as crucial prognostic indicators in the HIV landscape. The advent of antiretroviral therapy revolutionized the management of HIV by suppressing viral replication. A comprehensive examination of how ART impacts CD4/CD8 ratios, contributing to immune reconstitution and restoration of immune function, is discussed in this section. Immunosenescence, characterized by accelerated aging of the immune system, is a phenomenon observed in HIV. Elite controllers and long-term non-progressors represent unique subsets of individuals with HIV who exhibit remarkable control over viral replication without the need for immediate therapeutic intervention. While CD4/CD8 ratios provide valuable insights, their interpretation is not without challenges. The review underscores the pivotal role of CD4/CD8 ratios as key indicators of immune health in HIV. From prognostic markers to guides in therapeutic decision-making, CD4/CD8 ratios provide a window into the complex interplay between the virus and the host immune system.

Keywords*: CD4/CD8 ratio, T-cell subsets, HIV, immune response, disease progression, antiretroviral therapy, immunological monitoring*

Introduction

Citation: Obeagu EI, Obeagu, GU. Counting Cells, Shaping Fates: CD4/CD8 Ratios in HIV. *Elite Journal of Scientific Research and Review*, 2024; 2(1): 37-50

The immune system, a dynamic network of cells and molecules, serves as the body's primary defense against pathogens, including the human immunodeficiency virus (HIV).[1-3] Among the key orchestrators of immune responses are CD4 and CD8 T cells, whose delicate equilibrium plays a pivotal role in sustaining a functional immune system. The CD4/CD8 ratio, a numerical representation of the balance between these T-cell subsets, has emerged as a critical biomarker with profound implications for understanding, monitoring, and managing HIV infection. The CD4 T cells, often referred to as helper T cells, play a central role in coordinating immune responses by assisting other immune cells. In contrast, CD8 T cells, or cytotoxic T cells, are vital for directly targeting and eliminating infected cells. The delicate balance between these two T-cell subsets is essential for an effective and well-coordinated immune response. Historically, CD4/CD8 ratios have served as crucial prognostic indicators in HIV infection, offering insights into disease progression and outcomes. The decline in CD4 T cells, targeted by the virus, and alterations in the CD4/CD8 ratio provide valuable information about the status of the immune system and the potential trajectory of the disease. The introduction of antiretroviral therapy marked a transformative era in HIV management, suppressing viral replication and allowing for immune reconstitution. Immunosenescence, characterized by accelerated aging of the immune system, is a phenomenon observed in HIV-infected individuals. Elite controllers and long-term non-progressors represent intriguing subsets of individuals with HIV who exhibit exceptional control over viral replication without immediate therapeutic intervention.[4-32]

This review aims to explore the intricate dynamics of CD4 and CD8 T-cell biology in the context of HIV infection. From their pivotal roles in immune responses to the nuanced alterations during HIV pathogenesis, this exploration sets the stage for a deeper understanding of the CD4/CD8 ratio's significance as a biomarker in HIV prognosis and therapeutic decision-making. By delving into the molecular and immunological intricacies, this review contributes to the broader comprehension of HIV immunopathology and guides future research directions in the quest for more effective therapeutic interventions.

CD4 and CD8 T-Cell Biology

The immune system, a remarkable orchestra of cellular interactions and responses, relies heavily on the delicate balance between various T-cell subsets for effective defense against pathogens and maintenance of homeostasis. Among these, CD4 and CD8 T cells play central roles in orchestrating immune responses, and their equilibrium holds particular significance in the context of HIV infection. As the virus preferentially targets CD4 T cells, understanding the dynamics of CD4 and CD8 T-cell biology is essential for unraveling the complexities of HIV pathogenesis and progression. CD4 T cells, often referred to as helper T cells, serve as architects of the immune system. Recognizing antigens presented by antigen-presenting cells (APCs), CD4 T cells orchestrate immune responses by providing crucial signals to other immune cells. Their ability to differentiate into distinct effector subsets, including Th1, Th2, and regulatory T cells, underscores their versatility in shaping immune reactions tailored to specific threats. In contrast, CD8 T cells, known as cytotoxic or killer T cells, specialize in targeting and eliminating infected host cells. Through the recognition of antigens presented on the surface of infected cells, CD8 T cells unleash

cytotoxic mechanisms, including the release of perforins and granzymes, to eradicate the threat. This cellular immune response is pivotal for controlling viral infections, including HIV.[35-52]

HIV's insidious nature lies in its ability to exploit the very architects of immune responses – the CD4 T cells. The virus, binding to the CD4 receptor, gains entry into these cells, leading to their depletion and compromising the immune system's ability to mount an effective defense. This predilection for CD4 T cells sets the stage for the progressive immunodeficiency characteristic of HIV infection. The preferential targeting of CD4 T cells by HIV disrupts the delicate equilibrium between CD4 and CD8 T-cell populations. As CD4 T cells decline, CD8 T cells often undergo expansion in response to the ongoing viral replication. This imbalance, reflected in alterations of the CD4/CD8 ratio, becomes a hallmark of HIV infection and a key parameter in assessing disease progression. The CD4/CD8 ratio has emerged as a crucial prognostic indicator in HIV infection. A declining ratio is associated with an increased risk of opportunistic infections and other AIDS-related complications. Monitoring this ratio provides valuable insights into the trajectory of the disease and guides therapeutic interventions, particularly in the initiation of antiretroviral therapy (ART).[53-66]

Immune Dysregulation in HIV

The human immunodeficiency virus (HIV) remains a formidable global health challenge, characterized by its insidious assault on the immune system. At the heart of HIV pathogenesis lies a complex web of immune dysregulation, where the virus systematically undermines the very defenses designed to protect the host. A hallmark of HIV infection is the preferential targeting of CD4 T cells, the conductors of immune responses. The virus gains entry into these key orchestrators by binding to the CD4 receptor, leading to their progressive depletion. This assault on CD4 T cells underlies the immunodeficiency characteristic of HIV, leaving the host vulnerable to opportunistic infections and malignancies. HIV's impact extends beyond CD4 T cells, exerting a ripple effect on the CD4/CD8 ratio. As CD4 T cells decline, CD8 T cells often undergo expansion in response to the ongoing viral replication. This disruption in the equilibrium between CD4 and CD8 T cells serves as both a consequence and a contributor to immune dysregulation, influencing disease progression and prognosis. HIV further disrupts immune function by subverting the activity of antigen-presenting cells (APCs), including dendritic cells and macrophages. The virus hampers APC function, impairing the presentation of antigens to T cells and compromising the initiation of effective immune responses. This dysfunction contributes to the overall immunosuppressive milieu in HIV infection.[67-76]

Persistent immune activation and chronic inflammation represent a double-edged sword in HIV. While inflammation is a hallmark of an effective immune response, the sustained activation observed in HIV becomes detrimental.[77] The virus induces a state of systemic inflammation, fostering an environment conducive to viral replication and contributing to immune exhaustion. Prolonged exposure to HIV antigens induces a state of T-cell exhaustion, where T cells become functionally impaired and lose their ability to mount robust responses. The upregulation of inhibitory receptors, such as PD-1, on T cells further contributes to immune dysfunction. Strategies

employed by the virus, including immune evasion and escape mutations, exacerbate T-cell dysfunction. The dysregulation in HIV extends to B cells, compromising their ability to produce antibodies and mount effective humoral responses. Hypergammaglobulinemia, a hallmark of chronic HIV infection, reflects the persistent efforts of the immune system to combat the virus, albeit with impaired efficacy. The dysregulated immune milieu in HIV is further characterized by imbalances in cytokines and chemokines. Elevated levels of pro-inflammatory cytokines, such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), contribute to chronic inflammation, perpetuating a state of immune dysregulation.

Prognostic Value of CD4/CD8 Ratios

The immune system is an intricate network of cellular interactions designed to defend the host against pathogens and maintain physiological balance. Central to this defense are CD4 and CD8 T cells, crucial orchestrators of adaptive immunity.[78] In the realm of HIV, the virus's predilection for CD4 T cells and the consequential disruption of the CD4/CD8 ratio hold profound prognostic implications. CD4 T cells, as architects of immune responses, coordinate the activation of various immune effectors, while CD8 T cells act as sentinels of cellular immunity, eliminating infected cells. HIV's preferential targeting of CD4 T cells disrupts this balance, instigating a cascade of events that profoundly shape the course of infection. HIV's ability to exploit CD4 T cells by binding to the CD4 receptor initiates a cycle of immune dysregulation. As the virus replicates, CD4 T cells are depleted, triggering compensatory expansions of CD8 T cells. This immune dysregulation, characterized by altered T-cell subset ratios, serves as a crucial indicator of the evolving immunopathology in HIV. The CD4/CD8 ratio, reflecting the equilibrium between helper and cytotoxic T-cell subsets, emerges as a valuable biomarker with significant prognostic implications. A declining ratio is associated with an increased risk of opportunistic infections, AIDS-related complications, and mortality. Monitoring this ratio provides clinicians with critical insights into the immune status of individuals living with HIV.

The CD4/CD8 ratio offers prognostic insights at various stages of HIV infection. In the early stages, a lower baseline ratio may indicate a higher risk of disease progression. Longitudinal assessments further reveal the trajectory of immune recovery or deterioration, guiding therapeutic decisions, including the initiation of antiretroviral therapy (ART). The advent of ART revolutionized HIV management, significantly impacting CD4/CD8 ratios. Effective viral suppression through ART often leads to immune reconstitution, reflected in the restoration of CD4 T cells and normalization of the CD4/CD8 ratio. Understanding the nuances of this evolution is pivotal for predicting long-term health outcomes. While CD4 counts traditionally served as primary indicators of HIV progression, the CD4/CD8 ratio provides a more comprehensive picture. This ratio accounts for both CD4 and CD8 dynamics, offering a nuanced assessment of immune health. Its integration into clinical practice enhances the precision of prognostic evaluations.[78]

Impact of Antiretroviral Therapy

HIV infection heralds a complex interplay between the virus and the host immune system, resulting in progressive immune dysregulation. This dysregulation, marked by a cascade of events affecting various components of the immune system, lies at the crux of the pathogenesis and clinical manifestations of HIV/AIDS.[79] HIV's primary target, CD4 T cells, undergo progressive depletion, compromising the immune system's ability to mount adequate responses. This depletion, coupled with persistent viral replication and the establishment of viral reservoirs, sets the stage for chronic immune activation and dysregulation. The chronic activation of immune responses in HIV is a double-edged sword. While an initial robust immune reaction is mounted against the virus, the sustained activation leads to a state of exhaustion and dysfunction among immune cells. This chronic inflammatory environment contributes to the pathogenesis of HIV-associated complications, including cardiovascular diseases and neurocognitive disorders. Beyond CD4 T cells, the dysregulation extends to other T-cell subsets, notably CD8 T cells. The expansion and functional alterations of CD8 T cells, often in response to persistent antigenic stimulation, contribute to the observed immunological imbalances, such as an increased CD4/CD8 ratio. These perturbations are not only indicative of immune dysregulation but also hold prognostic value in predicting disease outcomes.

HIV-induced immune dysregulation also extends to B-cell populations. Hypergammaglobulinemia, polyclonal B-cell activation, and impaired antibody responses are characteristic features. The dysregulated B-cell function further contributes to compromised humoral immunity, impacting the host's ability to mount effective antibody responses against both HIV and opportunistic infections. Monocytes and macrophages, integral components of the innate immune system, are not spared from HIV-induced dysregulation. Persistent viral replication and the presence of viral proteins activate these cells, fostering a pro-inflammatory environment. This sustained activation has implications for tissue damage, immune exhaustion, and the progression of HIV-associated comorbidities. The impact of immune dysregulation in HIV is compounded in the presence of coinfections, such as hepatitis C and tuberculosis. Coinfections not only exacerbate the chronic inflammatory state but also contribute to additional challenges in managing HIV-associated immune dysregulation. Recognizing the intricate web of immune dysregulation in HIV is crucial for developing targeted therapeutic interventions. While antiretroviral therapy (ART) remains the cornerstone, adjunctive strategies aimed at modulating immune activation and restoring immune homeostasis are areas of active investigation.[79]

CD4/CD8 Ratio as a Therapeutic Endpoint

In the evolving landscape of HIV management, the CD4/CD8 ratio has emerged as a critical immunological parameter with implications extending beyond mere diagnostic and prognostic value. As therapeutic interventions for HIV have progressed, understanding the dynamic interplay between CD4 and CD8 T-cell subsets and their ratio becomes integral in gauging the efficacy of treatments, optimizing health outcomes, and guiding therapeutic decision-making. The historical significance of CD4 counts as a key determinant in initiating antiretroviral therapy (ART) is well-established. However, with advancements in our understanding of HIV immunopathology, the focus has expanded to encompass the CD4/CD8 ratio as a more nuanced indicator of immune

function. This section provides a historical context, highlighting the paradigm shift from CD4 counts to the CD4/CD8 ratio. A robust CD4/CD8 ratio has shown prognostic value, correlating with improved clinical outcomes and reduced risk of HIV-associated comorbidities. This section delves into the existing body of evidence linking the CD4/CD8 ratio to long-term health prospects, emphasizing its role in predicting disease progression, opportunistic infections, and overall mortality.[78]

Antiretroviral therapy, a cornerstone in HIV management, plays a pivotal role in immune reconstitution. Examining the impact of ART on the CD4/CD8 ratio provides insights into the effectiveness of treatment. Achieving a balanced ratio becomes a therapeutic goal, reflecting not only viral suppression but also the restoration of immune homeostasis. Despite effective viral suppression with ART, residual immune activation and inflammation persist in many individuals with HIV. Monitoring the CD4/CD8 ratio in this context becomes crucial, offering a window into the ongoing immune dysregulation. Strategies aimed at mitigating residual inflammation and restoring a favorable ratio are explored in this section. Recognizing the limitations of focusing solely on viral suppression, this section explores therapeutic approaches that extend beyond traditional antiretroviral strategies. Immunomodulatory interventions aimed at optimizing the CD4/CD8 ratio, including targeted anti-inflammatory agents, immunotherapies, and adjunctive therapies, are discussed for their potential in enhancing overall immune health. The heterogeneity in immune responses among individuals with HIV underscores the need for personalized and tailored treatment approaches. Integrating the CD4/CD8 ratio as a therapeutic endpoint allows clinicians to individualize care, optimizing interventions based on the unique immunological profiles of patients.[77]

Conclusion

The CD4/CD8 ratio has emerged as a dynamic and clinically relevant biomarker with profound implications for the management and prognosis of individuals living with HIV. The delicate balance between CD4 and CD8 T-cell subsets, disrupted by the virus's preferential targeting of CD4 T cells, serves as a sentinel of immune health and disease progression. This The prognostic value of the CD4/CD8 ratio in predicting disease progression and clinical outcomes cannot be overstated. A declining ratio often heralds an increased risk of opportunistic infections and AIDS-related complications, guiding timely therapeutic interventions. The advent of antiretroviral therapy (ART) has revolutionized HIV management, and the CD4/CD8 ratio stands as a critical parameter in assessing immune reconstitution and the effectiveness of treatment strategies. The normalization of the CD4/CD8 ratio under ART not only reflects successful viral suppression but also correlates with improved long-term health outcomes. Furthermore, the CD4/CD8 ratio holds promise as a therapeutic endpoint, guiding treatment decisions and providing insights into the overall immune health of individuals on ART. The pursuit of personalized medicine in HIV care involves not only achieving viral suppression but also restoring and maintaining a balanced immune profile, as reflected by the CD4/CD8 ratio. As new therapeutic modalities and interventions are explored, the CD4/CD8 ratio may serve as a crucial metric for assessing the success of these approaches in restoring immune homeostasis.

Citation: Obeagu EI, Obeagu, GU. Counting Cells, Shaping Fates: CD4/CD8 Ratios in HIV. *Elite Journal of Scientific Research and Review*, 2024; 2(1): 37-50

References

1. Guha D, Ayyavoo V. Innate immune evasion strategies by human immunodeficiency virus type 1. International Scholarly Research Notices. 2013;2013.
2. Sattler S. The role of the immune system beyond the fight against infection. The immunology of cardiovascular homeostasis and pathology. 2017:3-14.
3. Subramanian N, Torabi-Parizi P, Gottschalk RA, Germain RN, Dutta B. Network representations of immune system complexity. Wiley Interdisciplinary Reviews: Systems Biology and Medicine. 2015;7(1):13-38.
4. Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU. Under-nutrition among HIV-exposed Uninfected Children: A Review of African Perspective. Madonna University journal of Medicine and Health Sciences. 2022;2(3):120-127.
5. Obeagu EI, Alum EU, Obeagu GU. Factors associated with prevalence of HIV among youths: A review of Africa perspective. Madonna University journal of Medicine and Health Sciences. 2023;3(1):13-18. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/93.
6. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences. 2023 ;3(1):7-12. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/91.
7. Obeagu EI, Obeagu GU. An update on premalignant cervical lesions and cervical cancer screening services among HIV positive women. J Pub Health Nutri. 2023; 6 (2). 2023; 141:1-2. links/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf.
8. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
9. Omo-Emmanuel UK, Chinedum OK, Obeagu EI. Evaluation of laboratory logistics management information system in HIV/AIDS comprehensive health facilities in Bayelsa State, Nigeria. Int J Curr Res Med Sci. 2017;3(1): 21-38.DOI: 10.22192/ijcrms.2017.03.01.004
10. Obeagu EI, Obeagu GU, Musiimenta E, Bot YS, Hassan AO. Factors contributing to low utilization of HIV counseling and testing services. Int. J. Curr. Res. Med. Sci. 2023;9(2): 1-5.DOI: 10.22192/ijcrms.2023.09.02.001
11. Obeagu EI, Obeagu GU. An update on survival of people living with HIV in Nigeria. J Pub Health Nutri. 2022; 5 (6). 2022;129. links/645b4bfcf3512f1cc5885784/An-update-on-survival-of-people-living-with-HIV-in-Nigeria.pdf.
12. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-19.

13. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
14. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, Ikpeme M, Bassey JO, Paul AO. TB Infection Control in TB/HIV Settings in Cross River State, Nigeria: Policy Vs Practice. Journal of Pharmaceutical Research International. 2020;32(22):101-119.
15. Obeagu EI, Eze VU, Alaeboh EA, Ochei KC. Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. J BioInnovation. 2016; 5:464-471. links/592bb4990f7e9b9979a975cf/DETERMINATION-OF-HAEMATOCRIT-LEVEL-AND-IRON-PROFILE-STUDY-AMONG-PERSONS-LIVING-WITH-HIV-IN-UMUAHIA-ABIA-STATE-NIGERIA.pdf.
16. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. International Journal of Current Microbiology and Applied Sciences. 2015;4(4):911-916. https://www.academia.edu/download/38320140/Obeagu_Emmanuel_Ifeanyi_and_Obeagu__Getrude_Uzoma2.EMMA1.pdf.
17. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive measures and management of HIV/AIDS victims among parents in Umuna Orlu community of Imo state Nigeria. Int. J. Adv. Res. Biol. Sci. 2016;3(10): 55-65.DOI; 10.22192/ijarbs.2016.03.10.009
18. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75. links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf
19. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. Madonna University journal of Medicine and Health Sciences. 2022;2(3):110-119.
20. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA) and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State. Nigeria. J. Bio. Innov. 2016;5(1):24-30. links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf.
21. Igwe CM, Obeagu IE, Ogbuabor OA. Clinical characteristics of people living with HIV/AIDS on ART in 2014 at tertiary health institutions in Enugu, Nigeria. J Pub Health Nutri. 2022; 5 (6). 2022;130. links/645a166f5762c95ac3817d32/Clinical-characteristics-of-people-living-with-HIV-AIDS-on-ART-in-2014-at-tertiary-health-institutions-in-Enugu.pdf.
22. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. Int J Curr Res

Aca Rev. 2015; 3:139-144. https://www.academia.edu/download/38320159/Obeagu_Emmanuel_Ifeanyi3__et_al.IJCRAR.pdf.

23. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. Hematological indices o HIV seropositive subjects in Nnamdi Azikiwe University teaching hospital (NAUTH), Nnewi. Ann Clin Lab Res. 2018;6(1):1-4. links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf
24. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF. Impact of prevention of mother to child transmission (PMTCT) of HIV on positivity rate in Kafanchan, Nigeria. Int. J. Curr. Res. Med. Sci. 2017;3(2): 28-34.DOI: 10.22192/ijcrms.2017.03.02.005
25. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. Health Science Reports. 2023;6(8):e1450.
26. Obeagu EI, Amekpor F, Scott GY. An update of human immunodeficiency virus infection: Bleeding disorders. J Pub Health Nutri. 2023; 6 (1). 2023;139. links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf.
27. Obeagu EI, Scott GY, Amekpor F, Ofodile AC, Edoho SH, Ahamefula C. Prevention of New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life in Developing Countries. Madonna University journal of Medicine and Health Sciences. 2022;2(3):128-134. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/86.
28. Walter O, Anaebo QB, Obeagu EI, Okoroiwu IL. Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. Journal of Pharmaceutical Research International. 2022:29-34.
29. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, Ikpeme M, Bassey JO, Paul AO. Cascade variabilities in TB case finding among people living with HIV and the use of IPT: assessment in three levels of care in cross River State, Nigeria. Journal of Pharmaceutical Research International. 2020;32(24):9-18.
30. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis, Nigeria. J Pub Health Nutri. 2022; 5 (8). 2022;137. links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf.
31. Obeagu EI, Obeagu GU. A Review of knowledge, attitudes and socio-demographic factors associated with non-adherence to antiretroviral therapy among people living with HIV/AIDS. Int. J. Adv. Res. Biol. Sci. 2023;10(9):135-142.DOI: 10.22192/ijarbs.2023.10.09.015 links/6516faa61e2386049de5e828/A-Review-of-knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf

32. Obeagu EI, Onuoha EC. Tuberculosis among HIV Patients: A review of Prevalence and Associated Factors. Int. J. Adv. Res. Biol. Sci. 2023;10(9):128-134.DOI: 10.22192/ijarbs.2023.10.09.014 links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf.
33. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfected with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2017;3(5):100-104.DOI: 10.22192/ijcrms.2017.03.05.014 https://www.academia.edu/download/54317126/Haematological_indices_of_malaria_patients_coinfected_with_HIV.pdf
34. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, Eze GC, Essien UC, Madekwe CC, Madekwe CC, Vidya S, Kumar S. Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. South Asian Journal of Research in Microbiology. 2022;13(2):26-31.
35. Viola N, Kimono E, Nuruh N, Obeagu EI. Factors Hindering Elimination of Mother to Child Transmission of HIV Service Uptake among HIV Positive Women at Comboni Hospital Kyamuhunga Bushenyi District. Asian Journal of Dental and Health Sciences. 2023;3(2):7-14. http://ajdhs.com/index.php/journal/article/view/39.
36. Okorie HM, Obeagu Emmanuel I, Okpoli Henry CH, Chukwu Stella N. Comparative study of enzyme linked immunosorbent assay (Elisa) and rapid test screening methods on HIV, Hbsag, Hcv and Syphilis among voluntary donors in. Owerri, Nigeria. J Clin Commun Med. 2020;2(3):180-183.DOI: **DOI:** 10.32474/JCCM.2020.02.000137 links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunosorbent-Assay-ElISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf.
37. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Onah CE, Obeagu EI, Emeje PI, Awalu JC, Igbokwe GE. Use of ATP, GTP, ADP and AMP as an Index of Energy Utilization and Storage in HIV Infected Individuals at NAUTH, Nigeria: A Longitudinal, Prospective, Case-Controlled Study. Journal of Pharmaceutical Research International. 2021;33(47A):78-84.
38. Emannuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. Asian Journal of Pregnancy and Childbirth. 2023 Jul 29;6(1):203-211. http://research.sdpublishers.net/id/eprint/2819/.
39. Igwe MC, Obeagu EI, Ogbuabor AO, Eze GC, Ikpenwa JN, Eze-Steven PE. Socio-Demographic Variables of People Living with HIV/AIDS Initiated on ART in 2014 at Tertiary Health Institution in Enugu State. Asian Journal of Research in Infectious Diseases. 2022;10(4):1-7.
40. Vincent CC, Obeagu EI, Agu IS, Ukeagu NC, Onyekachi-Chigbu AC. Adherence to Antiretroviral Therapy among HIV/AIDS in Federal Medical Centre, Owerri. Journal of Pharmaceutical Research International. 2021;33(57A):360-368.

41. Igwe MC, Obeagu EI, Ogbuabor AO. ANALYSIS OF THE FACTORS AND PREDICTORS OF ADHERENCE TO HEALTHCARE OF PEOPLE LIVING WITH HIV/AIDS IN TERTIARY HEALTH INSTITUTIONS IN ENUGU STATE. Madonna University journal of Medicine and Health Sciences. 2022;2(3):42-57. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/75.
42. Madekwe CC, Madekwe CC, Obeagu EI. Inequality of monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. Madonna University journal of Medicine and Health Sciences. 2022;2(3):6-15. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/69
43. Echendu GE, Vincent CC, Ibebuike J, Asodike M, Naze N, Chinedu EP, Ohale B, Obeagu EI. WEIGHTS OF INFANTS BORN TO HIV INFECTED MOTHERS: A PROSPECTIVE COHORT STUDY IN FEDERAL MEDICAL CENTRE, OWERRI, IMO STATE. European Journal of Pharmaceutical and Medical Research, 2023; 10(8): 564-568
44. Nwosu DC, Nwanjo HU, Okolie NJ, Ikeh K, Ajero CM, Dike J, Ojiegbe GC, Oze GO, Obeagu EI, Nnatunanya I, Azuonwu O. BIOCHEMICAL ALTERATIONS IN ADULT HIV PATIENTS ON ANTIRETRQVIRAL THERAPY. World Journal of Pharmacy and Pharmaceutical Sciences, 2015; 4(3): 153-160**.** links/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETRQVIRAL-THERAPY.pdf.
45. Obeagu EI, Obeagu GU. Effect of CD4 Counts on Coagulation Parameters among HIV Positive Patients in Federal Medical Centre, Owerri, Nigeria. Int. J. Curr. Res. Biosci. Plant Biol. 2015;2(4):45-49.
46. Obeagu EI, Nwosu DC. Adverse drug reactions in HIV/AIDS patients on highly active antiretro viral therapy: a review of prevalence. Int. J. Curr. Res. Chem. Pharm. Sci. 2019;6(12):45-8.DOI: 10.22192/ijcrcps.2019.06.12.004 links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf.
47. Obeagu EI, Scott GY, Amekpor F, Obeagu GU. Implications of CD4/CD8 ratios in Human Immunodeficiency Virus infections. Int. J. Curr. Res. Med. Sci. 2023;9(2):6-13.DOI: 10.22192/ijcrms.2023.09.02.002 links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf.
48. Obeagu EI, Ochei KC, Okeke EI, Anode AC. Assessment of the level of haemoglobin and erythropoietin in persons living with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2016;2(4):29-33. links/5711c47508aeebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf.
49. Ifeanyi OE, Obeagu GU. The Values of CD4 Count, among HIV Positive Patients in FMC Owerri. Int. J. Curr. Microbiol. App. Sci. 2015;4(4):906-910. https://www.academia.edu/download/38320134/Obeagu_Emmanuel_Ifeanyi_and_Obeagu__Getrude_Uzoma.EMMA2.pdf.
50. Obeagu EI, Okeke EI, Anonde Andrew C. Evaluation of haemoglobin and iron profile study among persons living with HIV in Umuahia, Abia state, Nigeria. Int. J. Curr. Res. Biol. Med. 2016;1(2):1-5.

51. Alum EU, Ugwu OP, Obeagu EI, Okon MB. Curtailing HIV/AIDS Spread: Impact of Religious Leaders. Newport International Journal of Research in Medical Sciences (NIJRMS). 2023;3(2):28-31.
52. Obeagu EI, Obeagu GU, Paul-Chima UO. Stigma Associated With HIV. AIDS: A Review. Newport International Journal of Public Health and Pharmacy (NIJPP). 2023;3(2):64-67.
53. Alum EU, Obeagu EI, Ugwu OP, Aja PM, Okon MB. HIV Infection and Cardiovascular diseases: The obnoxious Duos. Newport International Journal of Research in Medical Sciences (NIJRMS). 2023;3(2):95-99.
54. Ibebuike JE, Nwokike GI, Nwosu DC, Obeagu EI. A Retrospective Study on Human Immune Deficiency Virus among Pregnant Women Attending Antenatal Clinic in Imo State University Teaching Hospital. *International Journal of Medical Science and Dental Research,* 2018; 1 (2):08-14. https://www.ijmsdr.org/published%20paper/li1i2/A%20Retrospective%20Study%20on%20Human%20Immune%20Deficiency%20Virus%20among%20Pregnant%20Women%20Attending%20Antenatal%20Clinic%20in%20Imo%20State%20University%20Teaching%20Hospital.pdf.
55. Obeagu EI, Obarezi TN, Omeh YN, Okoro NK, Eze OB. Assessment of some haematological and biochemical parametrs in HIV patients before receiving treatment in Aba, Abia State, Nigeria. Res J Pharma Biol Chem Sci. 2014; 5:825-830.
56. Obeagu EI, Obarezi TN, Ogbuabor BN, Anaebo QB, Eze GC. Pattern of total white blood cell and differential count values in HIV positive patients receiving treatment in Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria. International Journal of Life Science, Biotechnology and Pharama Research. 2014; 391:186-189.
57. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences. 2023; 3 (1): 7-12.
58. Oloro OH, Obeagu EI. A Systematic Review on Some Coagulation Profile in HIV Infection. International Journal of Innovative and Applied Research. 2022;10(5):1-11.
59. Nwosu DC, Obeagu EI, Nkwuocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Ezemma MC, Okpomeshine EA, Ozims SJ, Agu GC. Alterations in superoxide dismutiase, vitamins C and E in HIV infected children in Umuahia, Abia state. International Journal of Advanced Research in Biological Sciences. 2015;2(11):268-271.
60. Obeagu EI, Malot S, Obeagu GU, Ugwu OP. HIV resistance in patients with Sickle Cell Anaemia. Newport International Journal of Scientific and Experimental Sciences (NIJSES). 2023;3(2):56-59.
61. Ifeanyi OE, Uzoma OG, Stella EI, Chinedum OK, Abum SC. Vitamin D and insulin resistance in HIV sero positive individuals in Umudike. Int. J. Curr. Res. Med. Sci. 2018;4(2):104-108.
62. Ifeanyi OE, Leticia OI, Nwosu D, Chinedum OK. A Review on blood borne viral infections: universal precautions. Int. J. Adv. Res. Biol. Sci. 2018;5(6):60-66.
63. Nwovu AI, Ifeanyi OE, Uzoma OG, Nwebonyi NS. Occurrence of Some Blood Borne Viral Infection and Adherence to Universal Precautions among Laboratory Staff in Federal Teaching Hospital Abakaliki Ebonyi State. Arch Blood Transfus Disord. 2018;1(2).

Citation: Obeagu EI, Obeagu, GU. Counting Cells, Shaping Fates: CD4/CD8 Ratios in HIV. *Elite Journal of Scientific Research and Review*, 2024; 2(1): 37-50

64. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75.
65. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-19.
66. Obeagu EI, Obeagu GU, Ede MO, Odo EO, Buhari HA. Translation of HIV/AIDS knowledge into behavior change among secondary school adolescents in Uganda: A review. Medicine (Baltimore). 2023;102(49): e36599. doi: 10.1097/MD.0000000000036599. PMID: 38065920; PMCID: PMC10713174.
67. Anyiam AF, Arinze-Anyiam OC, Irondi EA, Obeagu EI. Distribution of ABO and rhesus blood grouping with HIV infection among blood donors in Ekiti State Nigeria. Medicine (Baltimore). 2023;102(47): e36342. doi: 10.1097/MD.0000000000036342. PMID: 38013335; PMCID: PMC10681551.
68. Echefu SN, Udosen JE, Akwiwu EC, Akpotuzor JO, Obeagu EI. Effect of Dolutegravir regimen against other regimens on some hematological parameters, CD4 count and viral load of people living with HIV infection in South Eastern Nigeria. Medicine (Baltimore). 2023;102(47): e35910. doi: 10.1097/MD.0000000000035910. PMID: 38013350; PMCID: PMC10681510.
69. Opeyemi AA, Obeagu EI. Regulations of malaria in children with human immunodeficiency virus infection: A review. Medicine (Baltimore). 2023;102(46): e36166. doi: 10.1097/MD.0000000000036166. PMID: 37986340; PMCID: PMC10659731.
70. Alum EU, Obeagu EI, Ugwu OPC, Samson AO, Adepoju AO, Amusa MO. Inclusion of nutritional counseling and mental health services in HIV/AIDS management: A paradigm shift. Medicine (Baltimore). 2023;102(41): e35673. doi: 10.1097/MD.0000000000035673. PMID: 37832059; PMCID: PMC10578718.
71. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. Health Sci Rep. 2023;6(8): e1450. doi: 10.1002/hsr2.1450. PMID: 37520460; PMCID: PMC10375546.
72. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR, Ugwu OP. Hematologic Support in HIV Patients: Blood Transfusion Strategies and Immunological Considerations. APPLIED SCIENCES (NIJBAS). 2023;3(3).
73. Obeagu EI, Ubosi NI, Uzoma G. Storms and Struggles: Managing HIV Amid Natural Disasters. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(11):14-25.
74. Obeagu EI, Obeagu GU. Human Immunodeficiency Virus and tuberculosis infection: A review of prevalence of associated factors. Int. J. Adv. Multidiscip. Res. 2023;10(10):56-62.
75. Obeagu EI, Malot S, Obeagu GU, Ugwu OP. HIV resistance in patients with Sickle Cell Anaemia. Newport International Journal of Scientific and Experimental Sciences (NIJSES). 2023;3(2):56-9.

76. Alum EU, Ugwu OP, Obeagu EI, Aja PM, Okon MB, Uti DE. Reducing HIV Infection Rate in Women: A Catalyst to reducing HIV Infection pervasiveness in Africa. International Journal of Innovative and Applied Research. 2023;11(10):01-6.
77. Pett SL, Kelleher A. Antiretroviral therapy-induced immune restoration in HIV infection: a double-edged sword? Expert Review of Anti-infective Therapy. 2004;2(3):335-339.
78. Cronkite DA, Strutt TM. The regulation of inflammation by innate and adaptive lymphocytes. Journal of immunology research. 2018.
79. Fülöp T, Herbein G, Cossarizza A, Witkowski JM, Frost E, Dupuis G, Pawelec G, Larbi A. Cellular senescence, immunosenescence and HIV. HIV and Aging. 2017; 42:28-46.